AMDAC November 5, 2015 on Fluoroquinolones in ABS, ABECB, uUTI – Part 1
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2015/11/AMDAC-slider.jpg?resize=640%2C180&ssl=1)
Only now, a few days before the actual AMDAC meeting, the FDA’s Briefing Document becomes available to the public. The topic of the December 5th meeting: Reappraisal of the risk/benefit of fluoroquinolones (FQ) in approved but “mild, self-limiting” disease indications in Continue reading AMDAC November 5, 2015 on Fluoroquinolones in ABS, ABECB, uUTI – Part 1